

## Alivira forays into European Veterinary Market

Acquires three companies to establish presence in Sweden, Belgium, Netherlands and Luxemburg

**Mumbai, December 03, 2015:** SeQuent Scientific Limited today announced that Alivira Animal Health Limited ("Alivira"), its subsidiary, has forayed into the European Veterinary Pharmaceutical markets through acquisition of three companies – N-Vet AB, Fendigo SA & Fendigo BV. The transactions are in line with Alivira's stated focus of becoming a leading global and integrated company in the Animal Health space.

Alivira has acquired 85% stake in the aforementioned companies with the current management retaining the balance stake. The structure of the transaction permits the current management team to drive the business while Alivira would provide a stronger framework for growth through a larger product portfolio, backed by regulatory compliance, global reach and integrated manufacturing capabilities.

### Background of the Acquired Companies

- **N-Vet AB:** Engaged in sales and marketing of veterinary pharmaceuticals and animal health products in Sweden
- **Fendigo SA:** Engaged in sales and marketing of veterinary pharmaceuticals and animal health products in Benelux region (Belgium and Luxembourg)
- **Fendigo BV:** Engaged in sales and marketing of veterinary pharmaceuticals and animal health products in Netherlands

Commenting on the development, **Mr. Manish Gupta, Managing Director of Alivira** - *"The acquisitions give a fillip to Alivira's vision to emerge as a power-house in the global animal health business. An established front-end presence available through these acquisitions will help us fast track the launch of our products in the European region. We are committed to further expanding our foot-prints in select market in the near future."*

The acquired business collectively had revenues of \$ 10 mn in 2014 with an EBITDA margin of 13%. All the transactions were signed and closed simultaneously. The acquired businesses will be integrated and consolidated with immediate effect, and will be EPS accretive.

### About Alivira Animal Health Limited

Alivira Animal Health Limited ("Alivira") is a vertically integrated Animal Healthcare company with three state of the art manufacturing facilities. The Company's API business is characterized by new product development capability, best-in-class infrastructure, wide product basket and long term relationships with most of the global animal health companies. In the formulations space, Alivira has established business presence in India, Turkey, Africa, MENA and South East Asia and has recently forayed in Europe. It has close to 200 dosage forms focused towards production animals produced in GMP compliant facilities in Turkey and India.

Alivira's long term vision is to become a global powerhouse for animal health built on a platform of superior quality and compliance.

## About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-SEQUENT/512529) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

SeQuent 's Animal Health business is operated through its subsidiary Alivira Animal Health Ltd and SeQuent is poised to emerge as a global powerhouse in animal health business, built on a platform of superior quality and compliance.

## For Queries, please contact

### **Kannan P R**

Chief Financial Officer

Tel: +91 80 67840327

[Kannan.pr@sequent.in](mailto:Kannan.pr@sequent.in)

### **Ankit Gupta**

Christensen Investor Relations

Tel : +91 22 42150210

[ankitgupta@christensenir.com](mailto:ankitgupta@christensenir.com)

### **SeQuent Registered Office**

SeQuent Scientific Limited  
301/A, 'Dosti Pinnacle',  
Plot No. E7, Road No. 22,  
Wagle Industrial Area, Thane (W),  
Maharashtra, India

**CIN:** L99999MH1985PLC036685

**BSE Code:**512529

**ISIN:** INE807F01019

**REUTERS:** SEQU.BO

**Website:** [www.sequent.in](http://www.sequent.in)

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.